Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.coi.2014.03.004 http://scihub22266oqcxt.onion/10.1016/j.coi.2014.03.004 C4118594!4118594 !24762410     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24762410 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Curr+Opin+Immunol 2014 ; 28 (ä): 102-6 Nephropedia Template TP {{tp|p=24762410 |t=2014. Interleukin 33: a switch-hitting cytokine |pdf=|usr=}}{{24762410 }} gab.com Text Interleukin 33: a switch-hitting cytokine JO: Curr Opin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=24762410 #FOAvip For many years IL-33 has been widely studied in the context of T helper type 2 (Th2)-driven inflammatory disorders. Interestingly, IL-33 has now emerged as a cytokine with a plethora of pleiotropic properties. Depending on the immune cells targeted by IL-33, it is reported to not only promote Th2 immunity, but also to induce T helper type 1 (Th1) immunity. Furthermore, recent studies have revealed that IL-33 can activate CD8(+) T cells. These new studies provide evidence for its beneficial role in antiviral and antitumor immunity. Here we review the evidence of IL-33 to drive protective T cell immunity plus its potential use as an adjuvant in vaccination and tumor therapy. Twit Text FOAVip Interleukin 33: a switch-hitting cytokine ????Curr Opin Immunol http://www.kidney.de/pget.php?&tw=1&pmid=24762410 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24762410 #FOAvip English Wikipedia <ref>{{Cite pmid|24762410 }}</ref> Interleukin 33: a switch-hitting cytokine #MMPMID24762410 Villarreal DO ; Weiner DB Curr Opin Immunol 2014[Jun]; 28 (ä): 102-6 PMID24762410 show ga For many years IL-33 has been widely studied in the context of T helper type 2 (Th2)-driven inflammatory disorders. Interestingly, IL-33 has now emerged as a cytokine with a plethora of pleiotropic properties. Depending on the immune cells targeted by IL-33, it is reported to not only promote Th2 immunity, but also to induce T helper type 1 (Th1) immunity. Furthermore, recent studies have revealed that IL-33 can activate CD8(+) T cells. These new studies provide evidence for its beneficial role in antiviral and antitumor immunity. Here we review the evidence of IL-33 to drive protective T cell immunity plus its potential use as an adjuvant in vaccination and tumor therapy. |Animals [MESH] |Cytokines/*immunology [MESH] |Humans [MESH] |Interleukins/*immunology [MESH] |Neoplasms/immunology [MESH] |Th1 Cells/immunology [MESH]Interleukin 33: a switch-hitting cytokine (epmc).pdf DeepDyve Pubget Overpricing